DCTH
$9.74
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Intraday
Recent News
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology
Delcath Systems (DCTH) announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn from Leiden University Medical Center’s Department of Medical Oncology. The publication, titled “Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma: a single-centre, open-label, randomised, phase 2 trial” is published in The Lancet Oncology and present
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Delcath Systems Inc (DCTH) reports record annual revenue of $85.2 million, outlines 2026 growth strategies, and addresses challenges in R&D expenses and seasonal impacts.
Delcath Systems Q4 Earnings Call Highlights
Delcath Systems (NASDAQ:DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding treatment-center capacity, increasing new patient starts, and strengthening referral networks. On the company’s f
Delcath (DCTH) Q4 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? David Hoffman: With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, General Manager, Interventional Oncology; Vojislav Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer.
Delcath Systems, Inc. Q4 2025 Earnings Call Summary
Moby summary of Delcath Systems, Inc.'s Q4 2025 earnings call